Overview
Start/End Dates
Locations
Eye Care Centre
Name/Title
Levina Ira, Study Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to evaluate the efficacy and safety of a novel gene therapy in participants with wet age-related macular degeneration (nAMD), a significant cause of vision loss for people worldwide. Current standard of care therapies require life-long intraocular injections that are typically repeated every 4-12 weeks to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. As such, gene therapy RGX-314 is being developed as a potential one-time treatment for nAMD.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
The purpose of this study is to evaluate the efficacy and safety of a novel gene therapy in participants with wet age-related macular degeneration (nAMD), a significant cause of vision loss for people worldwide. Current standard of care therapies require life-long intraocular injections that are typically repeated every 4-12 weeks to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. As such, gene therapy RGX-314 is being developed as a potential one-time treatment for nAMD.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
